Cited by 280Cancer survivorship and careOvarian cancer diagnosis and treatmentChildhood Cancer Survivors' Quality of Life

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Reliability and validity of the functional assessment of cancer therapy-ovarian

Basen-Engquist, Karen, Bodurka-Bevers, Diane, Fitzgerald, Mary A., Webster, Kimberly, Cella, David, Hu, Shaohua, Gershenson, David M.·2001·Journal of Clinical Oncology

DOI 10.1200/jco.2001.19.6.1809

Open this paper in CoChat — free account

Abstract

PURPOSE: To report the reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) in a consecutive series of outpatients with epithelial ovarian cancer. PATIENTS AND METHODS: Two hundred thirty-two ovarian cancer patients attending an outpatient gynecologic oncology clinic completed questionnaires at baseline. The patients' FACT-O scores were compared with their performance status, disease stage, treatment status, and other factors hypothesized to be related to quality of life. Patients received a second questionnaire either one week after baseline to assess the instrument's test-retest reliability and/or two months after baseline to evaluate its sensitivity to change in performance status. RESULTS: Internal consistency and test-retest reliability of the FACT-O were adequate. Overall, the scales correlated with other measures as expected; all correlations were in the hypothesized direction. Patients with advanced disease, poor performance status, and who were receiving active treatment had lower scores on physical, functional, and ovarian cancer-specific scales. The total FACT-O and emotional well-being scores were lower for patients with poor performance status and patients in active treatment. The FACT-O total and all subscale scores except emotional well-being were sensitive to decreases in performance status. CONCLUSION: Overall, the FACT-O provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies.

Integrity signals

Registry

Crossref · 10.1200/jco.2001.19.6.1809

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
Applied Multivariate Statistics for the Social Sciences
Stevens, J. P. (2012) · Routledge eBooks · doi:10.4324/9780203843130 · Cited by 10,652
A new scale of social desirability independent of psychopathology.
Crowne, D. P., & Marlowe, D. (1960) · Journal of Consulting Psychology · doi:10.1037/h0047358 · Cited by 8,686
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citation
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Self-citation
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress
Portenoy, R. K., Thaler, H. T., Kornblith, A. B., Lepore, J. M., Friedlander-Klar, H., Kiyasu, E., Sobel, K., Coyle, N., Kemeny, N. E., Norton, L., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90182-1 · Cited by 1,580
Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
Schipper, H., Clinch, J., McMurray, A., & Levitt, M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.472 · Cited by 1,052
Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
Zubrod, C. G., Schneiderman, M. A., Frei, E., Brindley, C. O., Gold, G. L., Shnider, B. I., Oviedo, R., Gorman, J. G., Jones, R., Jonsson, U., et al. (1960) · Journal of Chronic Diseases · doi:10.1016/0021-9681(60)90137-5 · Cited by 1,034
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation

Flagged first, then by citations

Show all 28 references

1 of the 28 references couldn’t be matched to a known paper.

Sorted by citations

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. Q., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,413
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Self-citation
Ovarian cancer
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P. J., Armstrong, D. K., Walker, J. L., Kim, B., Fujiwara, K., Tewari, K. S., O’Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Self-citation
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 427
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, É., Placido, S. D., Bologna, A., Weber, B. E., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H. Q., Birrer, M. J., Walker, J. L., DiSilvestro, P., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 369
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Monk, B. J., Poveda, A. M., Vergote, I. B., Raspagliesi, F., Fujiwara, K., Bae, D., Oaknin, A., Ray-Coquard, I. L., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 301
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Penson, R. T., Villalobos-Valencia, R., Cibula, D., Colombo, N., Leath, C. A., Bidziński, M., Kim, J., Nam, J., Mądry, R., Hernández, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02745 · Cited by 291
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02175-9 · Cited by 240
Self-citation
Randomized trial of ConquerFear: A novel, theoretically based psychosocial intervention for fear of cancer recurrence
Butow, P. N., Turner, J., Gilchrist, J., Sharpe, L., Smith, A. B., Fardell, J. E., Tesson, S., O’Connell, R., Girgis, A., Gebski, V. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.1257 · Cited by 228
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Walker, J. L., Brady, M. F., Wenzel, L. B., Fleming, G. F., Huang, H. Q., DiSilvestro, P., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01568 · Cited by 230
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
Hamanishi, J., Takeshima, N., Katsumata, N., Ushijima, K., Kimura, T., Takeuchi, S., Matsumoto, K., Ito, K., Mandai, M., Nakai, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00334 · Cited by 218
Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study
Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., & Cella, D. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3494 · Cited by 197
Self-citation
Reliability and Validity of the Functional Assessment of Chronic Illness Therapy-Palliative Care (FACIT-Pal) Scale
Lyons, K. D., Bakitas, M. A., Hegel, M. T., Hanscom, B. S., Hull, J. G., & Ahles, T. A. (2008) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2007.12.015 · Cited by 190
Predictors of Sexual Functioning in Ovarian Cancer Patients
Taylor, C. L. C., Basen-Engquist, K. M., Shinn, E. H., & Bodurka, D. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.150 · Cited by 192
Self-citation
Minimally important differences were estimated for the Functional Assessment of Cancer Therapy–Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches
Yost, K. J., Cella, D. F., Chawla, A., Holmgren, E. B., Eton, D. T., Ayanian, J. Z., & West, D. W. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.07.008 · Cited by 178
Self-citation
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Berek, J. S., Taylor, P. T., McGuire, W. P., Smith, L. M., Schultes, B. C., & Nicodemus, C. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8400 · Cited by 173
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Pujade-Lauraine, É., Banerjee, S. N., & Pignata, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00194 · Cited by 170
A literature review of the social and psychological needs of ovarian cancer survivors
Roland, K. B., Rodriguez, J. L., Patterson, J. R., & Trivers, K. F. (2013) · Psycho-Oncology · doi:10.1002/pon.3322 · Cited by 158
Quality of life and mood in women with gynecologic cancer: A one year prospective study
Lutgendorf, S. K., Anderson, B., Ullrich, P., Johnsen, E. L., Buller, R. E., Sood, A. K., Sorosky, J. I., & Ritchie, J. (2002) · Cancer · doi:10.1002/cncr.10155 · Cited by 142
Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization
Victorson, D., Barocas, J., Song, J., & Cella, D. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9398-2 · Cited by 141
Self-citation
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Friedlander, M. L., Gebski, V., Gibbs, E., Davies, L. C., Bloomfield, R., Hilpert, F., Wenzel, L. B., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30343-7 · Cited by 135
Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer
Weinrib, A., Sephton, S. E., DeGeest, K., Penedo, F. J., Bender, D., Zimmerman, B. M., Kirschbaum, C., Sood, A. K., Lubaroff, D. M., & Lutgendorf, S. K. (2010) · Cancer · doi:10.1002/cncr.25299 · Cited by 139
Loss of lifestyle: health behaviour and weight changes after becoming a caregiver of a family member diagnosed with ovarian cancer
Australian Ovarian Cancer Study Group, Beesley, V. L., Australian Ovarian Cancer Study—Quality of Life Study Investigators, Price, M. A., & Webb, P. M. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-1035-2 · Cited by 140
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Pujade-Lauraine, É., Selle, F., Scambia, G., Asselain, B. J. R., Marmé, F., Lindemann, K. Y., Colombo, N., Mądry, R., Glasspool, R. M., Vergote, I. B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3110 · Cited by 120
Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs
Butow, P. N., The Australian Ovarian Cancer Study Group, Price, M. A., Bell, M. L., Webb, P. M., deFazio, A., The Australian Ovarian Cancer Study Quality of Life Study Investigators, & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.01.002 · Cited by 119
Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers
Price, M. A., Butow, P. N., Costa, D. S. J., King, M. T., Aldridge, L. J., Fardell, J. E., DeFazio, A., & Webb, P. M. (2010) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03929.x · Cited by 116
Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations
Nyssen, O. P., Taylor, S. J., Wong, G., Steed, E., Bourke, L., Lord, J., Ross, C. A., Hayman, S., Field, V., Higgins, A., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20270 · Cited by 115
Associations between physical activity and quality of life in ovarian cancer survivors
Stevinson, C. D., Faught, W., Steed, H. L., Tonkin, K. S., Ladha, A. B., Vallance, J. K., Capstick, V. A., Schepansky, A., & Courneya, K. S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.03.033 · Cited by 112
Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study
Wenzel, L. B., Huang, H. Q., Monk, B. J., Rose, P. G., & Cella, D. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.147 · Cited by 110
Self-citation
What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)
Cella, D. F., Paul, D., Yount, S., Winn, R. J., Chang, C., Banik, D., & Weeks, J. C. (2003) · Cancer Investigation · doi:10.1081/cnv-120022366 · Cited by 107
Self-citation
Changes in supportive care needs after first‐line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs
Beesley, V. L., Price, M. A., Webb, P. M., O'Rourke, P. K., Marquart, L., Chenevix‐Trench, G., Australian Ovarian Cancer Study–Quality of Life Study Investigators, & Butow, P. N. (2012) · Psycho-Oncology · doi:10.1002/pon.3169 · Cited by 102
Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life
Hwang, K., Cho, O., & Yoo, Y. (2015) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2015.10.007 · Cited by 98
Fatigue in ovarian carcinoma patients
Holzner, B., Kemmler, G., Meraner, V., Maislinger, A., Kopp, M., Bodner, T., Nguyen-Van-Tam, D. P., Zeimet, A. G., Fleischhacker, W. W., & Sperner‐Unterweger, B. (2003) · Cancer · doi:10.1002/cncr.11253 · Cited by 97
Treatment Preferences in Recurrent Ovarian Cancer
Donovan, K. A., Greene, P. G., Shuster, J. L., Partridge, E. E., & Tucker, D. C. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6748 · Cited by 95
Effects of Reflexology and Progressive Muscle Relaxation on Pain, Fatigue, and Quality of Life during Chemotherapy in Gynecologic Cancer Patients
Dikmen, H. A., & Terzioğlu, F. (2018) · Pain Management Nursing · doi:10.1016/j.pmn.2018.03.001 · Cited by 98
Ovarian cancer survivors’ quality of life: a systematic review
Ahmed-Lecheheb, D., & Joly, F. (2016) · Journal of Cancer Survivorship · doi:10.1007/s11764-016-0525-8 · Cited by 95
Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: The roles of surgery and chemotherapy
von Gruenigen, V. E., Frasure, H. E., Jenison, E. L., Hopkins, M. P., & Gil, K. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.01.059 · Cited by 87
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Vergote, I. B., Scambia, G., O’Malley, D. M., CALSTER, B. V., Park, S., del Campo, J. M., Meier, W., Bamias, A., Colombo, N., Wenham, R. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30178-0 · Cited by 87
North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin‐induced peripheral neuropathy: A phase 3 randomized, double‐blind, placebo‐controlled study
Leal, A. D., Qin, R., Atherton, P. J., Haluska, P., Behrens, R. J., Tiber, C. H., Watanaboonyakhet, P., Weiss, M., Adams, P. T., Dockter, T., et al. (2014) · Cancer · doi:10.1002/cncr.28654 · Cited by 86
Sexual Self Schema as a Moderator of Sexual and Psychological Outcomes for Gynecologic Cancer Survivors
Carpenter, K. M., Andersen, B. L., Fowler, J. M., & Maxwell, G. L. (2008) · Archives of Sexual Behavior · doi:10.1007/s10508-008-9349-6 · Cited by 90
Patient reported late effects of gynecological cancer treatment
Grover, S., Hill‐Kayser, C. E., Vachani, C. C., Hampshire, M. K., DiLullo, G. A., & Metz, J. M. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.11.034 · Cited by 82
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
von Gruenigen, V. E., Huang, H. Q., Beumer, J. H., Lankes, H. A., Tew, W. P., Herzog, T. J., Hurria, A., Mannel, R. S., Rizack, T., Landrum, L. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.033 · Cited by 81
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Westin, S. N., Labrie, M., Litton, J. K., Blucher, A., Fang, Y., Vellano, C. P., Marszalek, J. R., Feng, N., Ma, X., Creason, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1656 · Cited by 84
Optimism, Distress, Health-Related Quality of Life, and Change in Cancer Antigen 125 Among Patients With Ovarian Cancer Undergoing Chemotherapy
de Moor, J. S., de Moor, C. A., Basen-Engquist, K. M., Kudelka, A. P., Bevers, M. W., & Cohen, L. G. (2006) · Psychosomatic Medicine · doi:10.1097/01.psy.0000222379.71389.91 · Cited by 80
Self-citation
Patient preferences in advanced or recurrent ovarian cancer
Havrilesky, L. J., Secord, A. A., Ehrisman, J. A., Berchuck, A., Valea, F. A., Lee, P. S., Gaillard, S. L., Samsa, G., Cella, D. F., Weinfurt, K. P., et al. (2014) · Cancer · doi:10.1002/cncr.28940 · Cited by 78
Self-citation
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study
Monk, B. J., Huang, H. Q., Burger, R. A., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., Boente, M. P., Liang, S. X., & Wenzel, L. B. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.038 · Cited by 74
Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer
Sailors, M. H., Bodurka, D. C., Gning, I., Ramondetta, L. M., Williams, L. A., Mendoza, T. R., Agarwal, S., Sun, C. C., & Cleeland, C. S. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.009 · Cited by 74
Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy‐gastric (FACT‐Ga) quality‐of‐life instrument
Garland, S. N., Pelletier, G., Lawe, A., Biagioni, B. J., Easaw, J., Eliasziw, M., Cella, D. F., & Bathe, O. F. (2010) · Cancer · doi:10.1002/cncr.25556 · Cited by 74
Self-citation
Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study
Newton, M. J., Hayes, S. C., Janda, M., Webb, P. M., Obermair, A., Eakin, E., Wyld, D., Gordon, L. G., & Beesley, V. L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-389 · Cited by 73
Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis
Siddiqui, F., Pajak, T. F., Bruner, D. W., Konski, A. A., Coyne, J. C., Gwede, C. K., Garden, A. S., Spencer, S. A., Jones, C. U., & Movsas, B. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.024 · Cited by 72
Quality of Life Considerations in Gynecologic Cancer
Penson, R. T., Wenzel, L. B., Vergote, I. B., & Cella, D. F. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60040-4 · Cited by 68
Self-citation
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
Colombo, N., Tomao, F., Panici, P. B., Nicoletto, M. O., Tognon, G., Bologna, A., Lissoni, A. A., DeCensi, A., Lapresa, M., Mancari, R., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.015 · Cited by 65
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study
Hess, L. M., Huang, H. Q., Hanlon, A. L., Robinson, W. R., Johnson, R. L., Chambers, S. K., Mannel, R. S., Puls, L. E., Davidson, S. A., Method, M. W., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.10.003 · Cited by 65
Active coping mediates the association between religion/spirituality and quality of life in ovarian cancer
Canada, A. L., Parker, P. A., de Moor, J. S., Basen‐Engquist, K., Ramondetta, L. M., & Cohen, L. G. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.045 · Cited by 71
Self-citation
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma
Advani, R. H., Peethambaram, P. P., Lum, B. L., Fisher, G. A., Hartmann, L. C., Long, H. J., Halsey, J., Holmlund, J., Dorr, A., & Sikic, B. I. (2004) · Cancer · doi:10.1002/cncr.11909 · Cited by 65
The functional assessment of cancer-vulvar: Reliability and validity
Janda, M., Obermair, A., Cella, D. F., Perrin, L. C., Nicklin, J., Ward, B. G., Crandon, A. J., & Trimmel, M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.01.047 · Cited by 64
Self-citation
Assessing Health-Related Quality of Life in Gynecologic Oncology
Luckett, T., King, M. T., Butow, P. N., Friedlander, M. L., & Paris, T. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181dad379 · Cited by 63
A review of issues surrounding quality of life among women with ovarian cancer
Arriba, L. N., Fader, A. N., Frasure, H. E., & von Gruenigen, V. E. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.014 · Cited by 62
Quality of life for patients with epithelial ovarian cancer
Sun, C. C., Ramirez, P. T., & Bodurka, D. C. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0693 · Cited by 62
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Friedlander, M. L., Moore, K. N., Colombo, N., Scambia, G., Kim, B., Oaknin, A., Lisyanskaya, A. S., Sonke, G. S., Gourley, C., Banerjee, S. N., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00098-x · Cited by 58
Recommended Patient-Reported Core Set of Symptoms and Quality-of-Life Domains to Measure in Ovarian Cancer Treatment Trials
Donovan, K. A., Donovan, H. S., Cella, D. F., Gaines, M. E., Penson, R. T., Plaxe, S. C., von Gruenigen, V. E., Bruner, D. W., Reeve, B. B., & Wenzel, L. B. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju128 · Cited by 58
Self-citation
An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer
Mizrahi, D., Broderick, C. R., Friedlander, M. L., Ryan, M., Harrison, M., Pumpa, K. L., & Naumann, F. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000460 · Cited by 57
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials
von Gruenigen, V. E., Huang, H. Q., Gil, K. M., Gibbons, H. E., Monk, B. J., Rose, P. G., Armstrong, D. K., Cella, D. F., & Wenzel, L. B. (2009) · Cancer · doi:10.1002/cncr.24520 · Cited by 57
Self-citation
Internet-Based Group Intervention for Ovarian Cancer Survivors: Feasibility and Preliminary Results
Kinner, E. M., Armer, J. S., McGregor, B. A., Duffecy, J., Leighton, S., Corden, M. E., Gauthier Mullady, J., Penedo, F. J., & Lutgendorf, S. K. (2018) · JMIR Cancer · doi:10.2196/cancer.8430 · Cited by 51
A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study
von Gruenigen, V. E., Huang, H. Q., Gil, K. M., Gibbons, H. E., Monk, B. J., Rose, P. G., Armstrong, D. K., Cella, D. F., & Wenzel, L. B. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.09.022 · Cited by 56
Self-citation
Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G
King, M. T., Stockler, M. R., Cella, D. F., Osoba, D., Eton, D. T., Thompson, J., & Eisenstein, A. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.05.001 · Cited by 58
Self-citation
Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life
Price, M., Bell, M. L., Sommeijer, D. W., Friedlander, M. L., Stockler, M. R., DeFazio, A., Webb, P. M., & Butow, P. N. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.031 · Cited by 60
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
for the GCIG Symptom Benefit group, King, M. T., Stockler, M. R., O’Connell, R. L., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., et al. (2017) · Quality of Life Research · doi:10.1007/s11136-017-1729-8 · Cited by 56
The Couples' Illness Communication Scale (CICS): development and evaluation of a brief measure assessing illness-related couple communication.
Arden-Close, E., Moss-Morris, R., Dennison, L., Bayne, L., & Gidron, Y. (2010) · British Journal of Health Psychology · doi:10.1348/135910709x476972 · Cited by 53
Mood States Associated with Transitory Physical Symptoms Among Breast and Ovarian Cancer Survivors
Badr, H., Basen-Engquist, K. M., Taylor, C. L. C., & de Moor, C. (2006) · Journal of Behavioral Medicine · doi:10.1007/s10865-006-9052-9 · Cited by 50
Self-citation
A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patients
von Gruenigen, V., Frasure, H. E., Fusco, N. L., Debernardo, R., Eldermire, E., Eaton, S., & Waggoner, S. E. (2010) · Cancer · doi:10.1002/cncr.25262 · Cited by 50
Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study
Correa, D. D., Root, J. C., Kryza‐Lacombe, M., Mehta, M., Karimi, S., Hensley, M. L., & Relkin, N. R. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9608-4 · Cited by 49
A new index of priority symptoms in advanced ovarian cancer
Jensen, S. E., Rosenbloom, S. K., Beaumont, J. L., Abernethy, A. P., Jacobsen, P. B., Syrjala, K. L., & Cella, D. F. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.09.025 · Cited by 51
Self-citation
Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy
von Gruenigen, V. E., Frasure, H. E., Kavanagh, M. B., Lerner, E., Waggoner, S. E., & Courneya, K. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.043 · Cited by 49
OVQUEST – Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors
Webber, K., Carolus, E., Mileshkin, L., Sommeijer, D. W., McAlpine, J. N., Bladgen, S., Coleman, R. L., Herzog, T. J., Sehouli, J., Nasser, S., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.08.009 · Cited by 50
Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Havrilesky, L. J., Secord, A. A., Darcy, K. M., Armstrong, D. K., & Kulasingam, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1961 · Cited by 47
Quality of life and mental health among women with ovarian cancer: examining the role of emotional and instrumental social support seeking
Hill, E. M. (2015) · Psychology Health & Medicine · doi:10.1080/13548506.2015.1109674 · Cited by 47
Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life
Beesley, V. L., Price, M. A., Butow, P. N., Green, A. C., Olsen, C. M., Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study — Quality of Life Study Investigators, & Webb, P. M. (2010) · Psycho-Oncology · doi:10.1002/pon.1834 · Cited by 47
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
LoRusso, P. M., Herbst, R. S., Rischin, D., Ranson, M., Calvert, H., Raymond, É., Kieback, D., Kaye, S. B., Gianni, L., Harris, A. L., et al. (2003) · PubMed · doi:10.25405/ncl.34650759 · Cited by 47
Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients
Brown, A. J., Sun, C. C., Urbauer, D. L., Bodurka, D. C., Thaker, P. H., & Ramondetta, L. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.005 · Cited by 45
Patient-Reported Outcomes in Phase II Cancer Clinical Trials: Lessons Learned and Future Directions
Wagner, L. I., Wenzel, L. B., Shaw, E., & Cella, D. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7275 · Cited by 45
Self-citation
Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach
Lutgendorf, S. K., Shinn, E. H., Carter, J., Leighton, S. L., Baggerly, K., Guindani, M., Fellman, B. M., Matzo, M. L., Slavich, G. M., Goodman, M. T., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.008 · Cited by 45
Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer
on behalf of the OPAL Study Group, Beesley, V. L., Smith, D. D., Nagle, C. M., Friedlander, M. L., Grant, P., DeFazio, A., & Webb, P. M. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4284-0 · Cited by 44
Quality of life in patients receiving treatment for gynecologic malignancies: Special considerations for patient care
Wenzel, L. B., Vergote, I. B., & Cella, D. F. (2003) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(03)90123-8 · Cited by 44
Self-citation
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study
Sjoquist, K. M., Friedlander, M. L., O'Connell, R. L., Voysey, M., King, M. T., Stockler, M. R., Oza, A. M., Gillies, K., Martyn, J. K., & Butow, P. N. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0175 · Cited by 43
Preoperative quality of life and surgical outcomes in gynecologic oncology patients: A new predictor of operative risk?
Doll, K. M., Snavely, A. C., Kalinowski, A. H., Irwin, D. E., Bensen, J. T., Bae-Jump, V. L., Boggess, J. F., Soper, J. T., Brewster, W. R., & Gehrig, P. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.002 · Cited by 40
Development of the Measure of Ovarian Symptoms and Treatment Concerns
King, M. T., Stockler, M. R., Butow, P. N., O’Connell, R. L., Voysey, M., Oza, A. M., Gillies, K., Donovan, H. S., Mercieca‐Bebber, R., Martyn, J. K., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000167 · Cited by 40
Written emotional disclosure for women with ovarian cancer and their partners: randomised controlled trial
Arden-Close, E. J., Gidron, Y., Bayne, L., & Moss-Morris, R. E. (2013) · Psycho-Oncology · doi:10.1002/pon.3280 · Cited by 40
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer
Bouberhan, S., Pujade-Lauraine, É., & Cannistra, S. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00314 · Cited by 40
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Lee, Y. C., King, M. T., O’Connell, R. L., Lanceley, A., Joly, F., Hilpert, F., Davis, A. J., Roncolato, F. T., Okamoto, A., Bryce, J., et al. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-003142 · Cited by 38
Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer
Friedlander, M. L., Stockler, M. R., O’Connell, R. L., Voysey, M., Oza, A. M., Gillies, K., Donovan, H. S., Martyn, J. K., Sjoquist, K. M., Butow, P. N., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000147 · Cited by 38
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve
Wilson, M. K., Friedlander, M. L., Joly, F., & Oza, A. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0297 · Cited by 38
Quality of Life in Ovarian Cancer
Grzankowski, K. S., & Carney, M. E. (2011) · Cancer Control · doi:10.1177/107327481101800107 · Cited by 35
Measuring Quality of Life in Cancer Survivors
Victorson, D. E., Cella, D. F., Wagner, L. I., Kramer, L. M. B., & Smith, M. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-34562-8_6 · Cited by 36
Self-citation
Development and validation of the functional assessment of cancer therapy nasopharyngeal cancer subscale
Tong, M. C. F., Lo, P. S. Y., Wong, K. H., Yeung, R. M. W., van Hasselt, C. A., Eremenco, S. L., & Cella, D. F. (2009) · Head & Neck · doi:10.1002/hed.21023 · Cited by 34
Self-citation
Spiritual Well-Being and Quality of Life of Women with Ovarian Cancer and Their Spouses
Frost, M. H., Johnson, M. E., Atherton, P. J., Petersen, W. O., Dose, A. M., Kasner, M. J., Burger, K. N., Sloan, J. A., & Pipe, T. B. (2011) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.09.001 · Cited by 35

Authors: Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M. A., Webster, K., Cella, D., Hu, S., & Gershenson, D. M.
Affiliations: Northwestern University (US)
From the University of Texas M.D. Anderson Cancer Center, Houston, TX; and Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University, Evanston, IL.
ORCID: Basen-Engquist, Karen
Webster, Kimberly
Cella, David
Hu, Shaohua
Gershenson, David M.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2001-03-15
Volume: 19
Issue: 6
Pages: 1809-1817
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2001.19.6.1809
OpenAlex: W2244770355
Cited by: 280
References: 28
Citations by year: 2026: 6 · 2025: 3 · 2024: 10 · 2023: 17 · 2022: 31 · 2021: 17 · 2020: 4 · 2019: 10 · 2018: 10 · 2017: 10 · 2016: 11 · 2015: 11 · 2014: 16 · 2013: 16 · 2012: 14
FWCI: 2.18
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
Keywords: ovarian cancer, quality of life, test-retest reliability, internal consistency, performance status, sensitivity to change, emotional well-being, functional status, instrument validation
MeSH terms: Activities of Daily Living, Adult, Aged, Clinical Trials as Topic, Emotions, Family Health, Female, Health Status, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Social Support, Reproducibility of Results, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reliability and validity of the functional assessment of cancer therapy-ovarian

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks